Psyence Biomedical Ltd.

Contributing Author

Recent Articles by Psyence Biomedical Ltd.

Oct-05	Psyence BioMed Partners with DEA-Registered Benuvia Operations to Establish U.S. Manufacture of Pharmaceutical-Grade Ibogaine PBM GlobeNewswire
Sep-28	Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation PBM GlobeNewswire
Sep-23	Psyence BioMed Announces Strategic Ibogaine Investment PBM GlobeNewswire
Sep-14	Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development PBM +11.11% GlobeNewswire
Aug-18	Psyence BioMed Welcomes U.S. Administration's Latest Action to Accelerate Ibogaine Development PBM +23.82% PBM -8.28% GlobeNewswire
May-15	Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing PBM GlobeNewswire
Apr-23	Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder PBM GlobeNewswire
Apr-20	Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source PBM +48.68% GlobeNewswire
Apr-17	Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine PBM +29.47% GlobeNewswire
Apr-08	Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5-Supported Clinical Activities PBM GlobeNewswire
Mar-11	Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone PBM GlobeNewswire
Mar-03	Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial PBM GlobeNewswire
Feb-20	Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment PBM PBM -10.80% GlobeNewswire
Feb-17	Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders PBM -9.71% GlobeNewswire
Feb-13	Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway PBM +9.96% GlobeNewswire
Feb-11	Psyence BioMed Announces Settlement of Shareholder Litigation PBM -6.92% GlobeNewswire
Jan-28	Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split PBM +22.01% PBM -6.42% GlobeNewswire
Jan-22	Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026 PBM -12.69% GlobeNewswire
Jan-20	Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date PBM GlobeNewswire
Jan-14	Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split PBM -13.90% GlobeNewswire
Jan-12	Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity PBM GlobeNewswire
Jan-05	Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash PBM -9.19% GlobeNewswire
Dec-19	Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial PBM -31.51% GlobeNewswire
Dec-09	Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science PBM -5.92% GlobeNewswire
Nov-25	Psyence BioMed Announces Groundbreaking Psilocybin Longevity Research Program PBM +5.96% GlobeNewswire
Nov-20	Psyence BioMed Reaches Major Breakthrough in Pharmaceutical-Grade Ibogaine Supply for Worldwide Clinical and Therapeutic Markets PBM -38.35% GlobeNewswire
Nov-12	Psyence BioMed Establishes Ibogaine Operations in Africa Through Strategic Investment in PsyLabs PBM GlobeNewswire
Nov-06	Psyence BioMed Doses Multiple Patients and Expands Clinical Sites in Phase IIb Study for Adjustment Disorder in Palliative Care PBM -7.10% GlobeNewswire
Nov-03	Psyence BioMed Strengthens Strategic Partnership with PsyLabs Through USD $3,500,000 Follow-On Investment PBM -5.06% GlobeNewswire
Aug-28	Psyence BioMed to Present at the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025 PBM GlobeNewswire
Aug-04	Corporate Update, August 2025 PBM +92.37% GlobeNewswire
Jul-31	Psyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine Production PBM -6.85% GlobeNewswire

Psyence Biomedical Ltd.

Recent Articles by Psyence Biomedical Ltd.

Upgrade your Finviz experience